Updating results

38 results for Anticoagulation

Sort: Relevance | Date

Andexanet alfa for reversing anticoagulation [ID1101]

In development [GID-TA10440] Expected publication date: 10 June 2020

Technology appraisal guidance In development

Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism

Technology appraisal guidance Published July 2012

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published December 2014

Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism

Technology appraisal guidance Published June 2015

Aortic valve reconstruction with processed bovine pericardium (IPG604)

Evidence-based recommendations on aortic valve reconstruction with processed bovine pericardium (using new valve made from chemically treated cow pericardium)

Interventional procedures guidance Published February 2018

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (TA256)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published May 2012

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation (AF)

Technology appraisal guidance Published August 2010 Last updated December 2012

Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (TA275)

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)

Technology appraisal guidance Published February 2013

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

Technology appraisal guidance Published August 2015

Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism (IPG400)

Evidence-based recommendations on thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation

Interventional procedures guidance Published June 2011

Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism (IPG349)

Evidence-based recommendations on percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation to prevent stroke

Interventional procedures guidance Published June 2010

Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in atrial fibrillation (AF)

Technology appraisal guidance Published March 2012

Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (IPG427)

Evidence-based recommendations on percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation (AF)

Interventional procedures guidance Published May 2012

Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults

Technology appraisal guidance Published January 2012

Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events (IPG472)

Evidence-based recommendations on percutaneous closure of patent foramen ovale (PFO/hole in the heart) to prevent recurrent cerebral embolic events

Interventional procedures guidance Published December 2013

Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

Technology appraisal guidance Published September 2015

Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (IPG651)

Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis (DVT) of the leg in adults

Interventional procedures guidance Published June 2019

Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis (IPG541)

Evidence-based recommendations on transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis

Interventional procedures guidance Published December 2015

Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (IPG653)

Evidence-based recommendations on valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic valve dysfunction in adults

Interventional procedures guidance Published June 2019

Stent placement for vena caval obstruction (IPG79)

Evidence-based recommendations on stent placement for vena caval obstruction

Interventional procedures guidance Published July 2004

Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension (IPG418)

Evidence-based recommendations on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension

Interventional procedures guidance Published January 2012

Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)

Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation (AF)

Interventional procedures guidance Published April 2006

Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (IPG294)

Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation (AF)

Interventional procedures guidance Published March 2009

Laparoscopic insertion of peritoneal dialysis catheter (IPG208)

Evidence-based recommendations on laparoscopic insertion of peritoneal dialysis catheter for treating end-stage renal disease (kidney failure)

Interventional procedures guidance Published February 2007

High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery (IPG184)

Evidence-based recommendations on high-intensity focused ultrasound for atrial fibrillation (AF) in association with other cardiac surgery

Interventional procedures guidance Published July 2006

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Evidence-based recommendations on rivaroxaban (Xarelto) for the prevention of venous thromboembolism after total hip or knee replacement in adults

Technology appraisal guidance Published April 2009

Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (TA157)

Evidence-based recommendations on dabigatran etexilate (Pradaxa) for the prevention of venous thromboembolism after hip or knee replacement surgery

Technology appraisal guidance Published September 2008

Joint distraction for ankle osteoarthritis (IPG538)

Evidence-based recommendations on joint distraction for ankle osteoarthritis

Interventional procedures guidance Published December 2015

Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (IPG563)

Evidence-based recommendations on percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation (AF) in adults

Interventional procedures guidance Published July 2016

Chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer (IPG488)

Evidence-based recommendations on chemosaturation via percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic liver cancer

Interventional procedures guidance Published May 2014

Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

Evidence-based recommendations on ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism (PE)

Interventional procedures guidance Published June 2015

Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block (TA324)

Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block

Technology appraisal guidance Published November 2014

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)

Technology appraisal guidance Published December 2016

Alteplase for treating acute ischaemic stroke (TA264)

Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)

Technology appraisal guidance Published September 2012

Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

Evidence-based recommendations on clopidogrel (Plavix) and modified-release dipyridamole (Persantin/Asasantin Retard) for preventing occlusive vascular events

Technology appraisal guidance Published December 2010

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)

Technology appraisal guidance Published March 2015

Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)

Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic, or locally recurrent non-small-cell lung cancer

Technology appraisal guidance Published July 2015